Hsbc Holdings PLC Sells 140,805 Shares of OraSure Technologies, Inc. $OSUR

Hsbc Holdings PLC reduced its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 60.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,980 shares of the medical instruments supplier’s stock after selling 140,805 shares during the period. Hsbc Holdings PLC owned approximately 0.12% of OraSure Technologies worth $310,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Private Management Group Inc. purchased a new position in shares of OraSure Technologies in the 1st quarter worth $14,886,000. American Century Companies Inc. grew its stake in shares of OraSure Technologies by 6.8% in the 1st quarter. American Century Companies Inc. now owns 2,505,124 shares of the medical instruments supplier’s stock worth $8,442,000 after buying an additional 159,287 shares in the last quarter. Millennium Management LLC grew its stake in shares of OraSure Technologies by 16.7% in the 4th quarter. Millennium Management LLC now owns 2,158,450 shares of the medical instruments supplier’s stock worth $7,792,000 after buying an additional 308,420 shares in the last quarter. Systematic Financial Management LP grew its stake in shares of OraSure Technologies by 33.7% in the 4th quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier’s stock worth $6,042,000 after buying an additional 421,497 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of OraSure Technologies by 180.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,517,541 shares of the medical instruments supplier’s stock worth $5,478,000 after buying an additional 976,475 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Trading Down 6.5%

OSUR stock opened at $3.14 on Thursday. OraSure Technologies, Inc. has a 12 month low of $2.36 and a 12 month high of $4.60. The company has a 50-day moving average price of $3.09 and a 200 day moving average price of $3.09. The stock has a market cap of $229.65 million, a PE ratio of -4.69 and a beta of 0.44.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Evercore ISI reissued an “in-line” rating and issued a $3.00 price objective on shares of OraSure Technologies in a research note on Monday, May 19th. Wall Street Zen raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 17th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, OraSure Technologies presently has a consensus rating of “Hold” and an average price target of $3.00.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.